TG Therapeutics, Inc. (TGTX): Price and Financial Metrics
Today's Latest Price: $26.07 USD
Oct 26 8:27pm Add TGTX to Watchlist Sign Up
Buy & Hold Grade
Peer Grade Industry Rank
TGTX Stock Summary Tg Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 8.68% of US listed stocks. Of note is the ratio of Tg Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 9.61% of US stocks have a lower such ratio. With a price/sales ratio of 22,688.54, Tg Therapeutics Inc has a higher such ratio than 99.95% of stocks in our set. If you're looking for stocks that are quantitatively similar to Tg Therapeutics Inc, a group of peers worth examining would be NK, CYAD, TRVN, ATHX, and PSTI. TGTX's SEC filings can be seen here. And to visit Tg Therapeutics Inc's official web site, go to www.tgtherapeutics.com.
TGTX Price/Volume Stats
TG Therapeutics, Inc. (TGTX) Company Bio
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company was founded in 1993 and is based in New York, New York.
TGTX Latest News Stream
All News Types
Commentary Corp. News Cramer Earnings Hedge Fund New Coverage (Bullish) Product News PT Raised PT Set (Bullish) Rating Reiterated (Bearish) Rating Reiterated (Bullish) Resumes Coverage (Bullish) Stock Offering
Loading, please wait...
Latest TGTX News From Around the Web
Below are the latest news stories about Tg Therapeutics Inc that investors may wish to consider to help them evaluate TGTX as an investment opportunity.
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Avid Bioservices Inc (NASDAQ: CDMO ) ( reacted to strong quarterly results) BioLife Solutions Inc (NASDAQ: BLFS ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Edwards Lifesciences Corp (NYSE: EW ) Evogene Ltd (NASDAQ: EVGN ) Fortress Biotech (NASDAQ: FBIO ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) (priced its 5.27-million-share common stock offering at $33 per share) Inspire Medical Systems Inc (NYSE: INSP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp ...
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) 10X Genomics Inc (NASDAQ: TXG ) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Catalent Inc (NYSE: CTLT ) Evogene Ltd (NASDAQ: EVGN ) (announced $10 million equity investment led by ARK Investment Management) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PPD Inc (NASDAQ: PPD ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 1) Acasti Pharma Inc (NASDAQ: ACST ) ADiTx Therapeutics...
Under Priority Review status, the FDA accepts TG Therapeutics' ([[TGTX]] +4.9%) marketing application for umbralisib for the treatment of patients with previously treated marginal zone lymphoma ((MZL)) who have received at least one prior anti-CD20 based regimen and follicular lymphoma ((FL)) who have received at least two prior systemic therapies.The...
TG Therapeutics (NASDAQ: TGTX ) shares are trading higher on Thursday after the company announced that the FDA accepted its new drug application for its Umbralisib as a treatment for patients with the previously-treated marginal zone Lymphoma and … Full story available on Benzinga.com
TG Therapeutics (TGTX): Q2 GAAP EPS of -$0.47 misses by $0.13.Revenue of $0.04M in-line (flat Y/Y).Press Release...
Read More 'TGTX' Stories Here
TGTX Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.7406 seconds.